Under non-inflammatory conditions HLA class II is predominantly expressed on hematopoietic cells. Therefore, donor CD4 T-cells after allogeneic stem cell transplantation (alloSCT) may mediate graft-vs.-leukemia reactivity without graft-vs.-host disease (GVHD). We analyzed immune responses in four patients converting from mixed to full donor chimerism without developing GVHD upon purified CD4 donor lymphocyte infusion (DLI) from their HLA-identical sibling donor after T-cell depleted alloSCT. In vivo activated T-cells were clonally isolated after CD4 DLI. Of the alloreactive T-cell clones, 96% were CD4 positive, illustrating the dominant role of CD4 T-cells in the immune responses. We identified 9 minor histocompatibility antigens (MiHA) as ...
AbstractAlloreactive (allo)-HLA–directed T cell responses after HLA-mismatched allogeneic hematopoie...
AbstractDonor lymphocyte infusions (DLIs) have been demonstrated to induce clinical responses in pat...
Persistent complete donor chimerism is an important clinical indicator for remissions of hematologic...
Under non-inflammatory conditions HLA class II is predominantly expressed on hematopoietic cells. Th...
Allogeneic stem cell transplantation (alloSCT) can be a curative treatment for h...
Allogeneic hematopoietic stem cell transplantation (alloSCT) is a potentially curative treatment for...
After HLA class I-mismatched stem cell transplantation, allo-HLA–directed CD8 T cell responses can b...
BACKGROUND: After allogeneic hematopoietic stem-cell transplantation (HSCT), donor-derived T cells m...
AbstractClinical studies have demonstrated that HLA-DPB1–mismatched allogeneic stem cell transplanta...
In allo-SCT, an immune reaction between donor T cells and recipient histocompatibility antigens (mHa...
Adoptive immunotherapy with donor lymphocyte infusion (DLI) after allogeneic stem cell transplantati...
Allo-HLA reactive T-cells can mediate graft versus host disease (GVHD) after HLA mismatched stem cel...
Stem cell transplantation (SCT) is an accepted treatment for patients with hematological malignancie...
<div><p>Persistent complete donor chimerism is an important clinical indicator for remissions of hem...
AbstractAllogeneic stem cell transplantation (allo-SCT) can induce remission in patients with hemato...
AbstractAlloreactive (allo)-HLA–directed T cell responses after HLA-mismatched allogeneic hematopoie...
AbstractDonor lymphocyte infusions (DLIs) have been demonstrated to induce clinical responses in pat...
Persistent complete donor chimerism is an important clinical indicator for remissions of hematologic...
Under non-inflammatory conditions HLA class II is predominantly expressed on hematopoietic cells. Th...
Allogeneic stem cell transplantation (alloSCT) can be a curative treatment for h...
Allogeneic hematopoietic stem cell transplantation (alloSCT) is a potentially curative treatment for...
After HLA class I-mismatched stem cell transplantation, allo-HLA–directed CD8 T cell responses can b...
BACKGROUND: After allogeneic hematopoietic stem-cell transplantation (HSCT), donor-derived T cells m...
AbstractClinical studies have demonstrated that HLA-DPB1–mismatched allogeneic stem cell transplanta...
In allo-SCT, an immune reaction between donor T cells and recipient histocompatibility antigens (mHa...
Adoptive immunotherapy with donor lymphocyte infusion (DLI) after allogeneic stem cell transplantati...
Allo-HLA reactive T-cells can mediate graft versus host disease (GVHD) after HLA mismatched stem cel...
Stem cell transplantation (SCT) is an accepted treatment for patients with hematological malignancie...
<div><p>Persistent complete donor chimerism is an important clinical indicator for remissions of hem...
AbstractAllogeneic stem cell transplantation (allo-SCT) can induce remission in patients with hemato...
AbstractAlloreactive (allo)-HLA–directed T cell responses after HLA-mismatched allogeneic hematopoie...
AbstractDonor lymphocyte infusions (DLIs) have been demonstrated to induce clinical responses in pat...
Persistent complete donor chimerism is an important clinical indicator for remissions of hematologic...